HZNP - Horizon's Uplizna reduces severity of attacks in neuro disease

Horizon Therapeutics (NASDAQ:HZNP) said a new analysis showed that Uplizna reduced the severity of attacks and levels of key disease-related biomarkers in people with Neuromyelitis Optica Spectrum Disorder (NMOSD). Uplizna is approved in the U.S. to treat NMOSD in adults who are anti-aquaporin-4 (AQP4) antibody positive. The company said treatment of NMOSD aims to reduce acute attacks associated with the disease, which can cause irreversible damage to the optic nerve, spinal cord, brain and brain stem. During the 28-week randomized-controlled period (RCP) of the N-MOmentum phase 2/3 trial, 89% of 161 patients receiving Uplizna remained attack-free compared to 58% of 52 patients in the placebo group. A new post hoc analysis was carrie out to understand the effect of Uplizna on the severity of attacks in the 11% of people who were not attack-free after receiving the drug. Of the 18 attacks that occurred in the Uplizna treatment group during the RCP, 12 were minor and

For further details see:

Horizon's Uplizna reduces severity of attacks in neuro disease